In a report, titled “Hematology Diagnostics Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 – 2023,” Transparency Market Research presents a comprehensive overview of the factors impacting the growth trajectory of the global market for hematology diagnostics between 2015 and 2023.
Hematology is a branch of medicine dealing with the diagnosis, treatment, and prevention of ailments related to the bone marrow, blood, immunology, the vascular system, and hemostasis (blood clotting). Hematological tests are carried out to diagnose various blood-related diseases such as anemia, leukemia, blood cancer, and autoimmune disorders, among others. The method encompasses various in vitro diagnostic (IVD) techniques such as hemostasis, molecular diagnostics, blood analysis, flow cytometry, and immunodiagnostics, which help in measuring various parameters of blood with improved precision at a comparatively lower cost.
The increasing incidence of blood-related disorders has been a key factor driving the global market for hematology diagnostics. As per data released by the Leukemia & Lymphoma Society (LLS), in the U.S. alone, approximately 1.6 million new cases of cancer were reported in 2015. About 9.8% of this demographic were diagnosed with leukemia, lymphoma, and myeloma. Additionally, as per the findings of the National Hemophilia Foundation, approximately 400,000 cases of people suffering from hemophilia are registered globally. With the population of people aged above 65 years being projected to reach over 83.7 million by 2050, as per the Administration for Community Living, which is twice that estimated in 2012, the market for hematology diagnostics is anticipated to exponentially grow in the near future.
Get Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=8848
It is therefore extremely important for vendors operating in the market for hematology diagnostics to be well aware of the market’s present dynamics and how various factors will shape its future. The information comprised in the report is aimed at assisting the market stakeholders with insights pertaining to the prevailing trends and projected factors that may influence the market’s growth trajectory over the forecast period.
Providing in-depth information pertaining to the technological developments and government policies supporting the further development of healthcare infrastructure across the most lucrative regions, the report makes for a resourceful guidebook for those seeking pertinent information about the hematology diagnostics market.
The report broadly classifies the global hematology diagnostics market on the basis of end user, product, and geography. By product, the market is bifurcated into hematology reagents and hematology analyzers. Based on end user, the market is segmented into clinical laboratories, hospitals, research institutes, and academics institutes.
Regionally, the global hematology diagnostics market constitutes Asia Pacific, Europe, North America, Latin America, and the Middle East and Africa. Of these, North America presently dominates the global hematology diagnostics market. However, the market in Asia Pacific is expected to exhibit the highest CAGR during the forecast period.
To provide a holistic overview of the prevailing competitive scenario of the market for hematology diagnostics, the report profiles some of the most prominent vendors operating in the market, such as HemoCue AB, Beckman Coulter, Sysmex, Abbott Laboratories, Mindray Medical HORIBA, Ltd., International Limited., Roche Diagnostics A/S, Siemens AG, and Bio-Rad Laboratories, Inc.
